-
1 week ago | 
bioprocessintl.com | Shreeyashi Ojha
Tokyo-headquartered Asahi Kasei has established Asahi Kasei Life Science to operate its bioprocess businesses, effective 1 April 2025. The vertical includes Asahi Kasei’s contract research organization (CRO) testing services, provided through ViruSure (acquired in 2019) and Bionique (acquired in 2021). It also incorporates its contract development and manufacturing organization (CDMO), Bionova, which the company acquired in 2022.
-
1 week ago | 
bioprocessintl.com | Shreeyashi Ojha
DEPOSITPHOTOS/zlatovlaska2008With an investment of ¥16.8 billion ($118 million), the 510,000 square-foot facility will use Kyowa’s antibody technology and protein engineering to manufacture drug substances. The GMP compliant plant will utilize single-use technology to reduce the risk of cross-contamination between products.
-
2 weeks ago | 
bioprocessintl.com | Shreeyashi Ojha
INCOG investing in Indiana DepositPhotos/gustavofrazaoThe expansion will provide device assembly capacity for autoinjectors, pens, wearable injectors, and syringe accessorizing. The site will eventually house a team of more than 350 employees. In February 2024, the contract development and manufacturing organization (CDMO) invested $75 million, adding Optima syringe and cartridge filling line to meet the burgeoning syringe and cartridge filling demand.
-
2 weeks ago | 
bioprocessintl.com | Shreeyashi Ojha
The Seattle-based firm broke ground on a four-story, 20,000 square-meter facility in January 2024. With an investment of ¥ 50 billion ($325 million), the plant will deal in mammalian-based protein biologics, cell therapies, and messenger RNA (mRNA). It is expected to create 400 jobs locally.
-
2 weeks ago | 
bioprocessintl.com | Shreeyashi Ojha
Contract development and manufacturing organization (CDMO) Veranova has appointed Scott Zugel as global vice president of analytical research development operations. Zugel, a veteran with over two decades of experience, joins the Massachusetts-based firm after serving as the head of analytical development at Takeda, where he established the company’s first internal metrology team for analytical testing labs.
-
3 weeks ago | 
bioprocessintl.com | Shreeyashi Ojha
Contract development and manufacturing organization (CDMO) National Resilience is constructing a 190,000 square-foot plant in Blue Ash, Ohio. This expansion will support operations at the West Chester plant by adding advanced automation for assembling and packaging drug products filled there. Additionally, the facility includes a cold and ambient storage space.
-
3 weeks ago | 
bioprocessintl.com | Shreeyashi Ojha
Self-proclaimed integrated development and manufacturing organization (IDMO) Cellares has confirmed the construction of five commercial-scale facilities across Europe and Japan. Though the locations of these facilities were not disclosed, the firm told BioProcess Insider that these cell therapy-focused “IDMO Smart Factories” will use robotics to produce up to ten times more batches at nearly half the cost, while its headquarters in San Francisco, California will support clinical trials.
-
3 weeks ago | 
bioprocessintl.com | Shreeyashi Ojha
With an investment of $75 million, the facility will focus on advanced viral vector production, designed to produce high-titer viral vectors including adeno-associated viruses (AAVs), lentivirus, and adenovirus, essential for CGT production. Bharat Biotech anticipates launching its first therapy for critical conditions, including hematological malignancies and inherited blood disorders, by 2028.
-
3 weeks ago | 
bioprocessintl.com | Shreeyashi Ojha
Dyadic International, in collaboration with FBS, will assess whether it's C1 filamentous fungus can produce antigens faster and more cost-effectively than mammalian cell-based methods. Of the total $4.5 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI), Dyadic will receive $2.4 million.
-
4 weeks ago | 
bioprocessintl.com | Shreeyashi Ojha
At Terrapin’s Advanced Therapies Week in London, UK, Joshi Venugopal, general manager and head of Europe at Novartis Gene Therapies, explored the trajectory of gene therapies by comparing them to the evolution of various other groundbreaking technologies. He illustrated how some innovations, such as social media, have seen steady growth, while others, like Web3, have surged and faded.
